Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes
by Prateek Chopra | July 3, 2026 | Diabetes Conferences | ADA 2026 Cardiovascular Risk Assessment Methods Study Population Key Findings Effect of Finerenone Clinical Implications Low-grade inflammation and obesity jointly contribute to cardiovascular risk in CKD and T2D. Finerenone maintained consistent cardioprotective benefits across all hsCRP and BMI categories, supporting its use for cardiovascular risk reduction in this high-risk […]